Patents by Inventor Katharine Grant-Young
Katharine Grant-Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124417Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: October 1, 2020Publication date: April 18, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Kap-Sun YEUNG, Denis R. ST. LAURENT, Li-Qiang SUN, Zhiwei YIN, Katharine A. GRANT-YOUNG, Paul Michael SCOLA
-
Patent number: 10882844Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: GrantFiled: December 19, 2017Date of Patent: January 5, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Kap-Sun Yeung, Katharine A. Grant-Young, Li-Qiang Sun, David R. Langley, Denis R. St. Laurent, Paul M. Scola
-
Patent number: 10745382Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: GrantFiled: October 11, 2016Date of Patent: August 18, 2020Assignee: bristol-myers squibb companyInventors: Kap-Sun Yeung, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
-
Patent number: 10590105Abstract: The present disclosure generally relates to compounds of formula (I), wherein R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: GrantFiled: July 5, 2017Date of Patent: March 17, 2020Assignee: Bristol-Meyers Squibb CompanyInventors: Kap-Sun Yeung, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, Zhaoxing Meng, Paul Michael Scola
-
Patent number: 10538555Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: September 11, 2014Date of Patent: January 21, 2020Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Kevin W. Gillman, Qian Zhao, Katharine A. Grant-Young, Paul Michael Scola, Lyndon A. M. Cornelius
-
Publication number: 20190352280Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: December 19, 2017Publication date: November 21, 2019Applicant: Bristol-Myers Squibb CompanyInventors: Kap-Sun YEUNG, Katharine A. GRANT-YOUNG, Li-Qiang SUN, David R. LANGLEY, Denis R. ST. LAURENT, Paul M. SCOLA
-
Publication number: 20190185450Abstract: The present disclosure generally relates to compounds of formula (I), wherein R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: July 5, 2017Publication date: June 20, 2019Inventors: Kap-Sun YEUNG, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, Zhaoxing Meng, Paul Michael Scola
-
Patent number: 10143746Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: March 1, 2017Date of Patent: December 4, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Martin Patrick Allen, Eric P. Gillis, David R. Langley, Michael Matthew Miller, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Katharine A. Grant-Young, Nicholas A. Meanwell, Paul Michael Scola
-
Patent number: 10144706Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: GrantFiled: August 29, 2017Date of Patent: December 4, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Kap-Sun Yeung, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, David R. Langley, Piyasena Hewawasam, Tao Wang, Zhongxing Zhang, Zhaoxing Meng, Li-Qiang Sun, Eric Mull, Paul Michael Scola
-
Publication number: 20180057455Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: August 29, 2017Publication date: March 1, 2018Inventors: KAP-SUN YEUNG, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, David R. Langley, Piyasena Hewawasam, Tao Wang, Zhongxing Zhang, Zhaoxing Meng, Li-Qiang Sun, Eric Mull, Paul Michael Scola
-
Publication number: 20170260237Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: September 11, 2014Publication date: September 14, 2017Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Kevin W. Gillman, Qian Zhao, Katharine A. Grant-Young, Paul Michael Scola, Lyndon A.M. Cornelius
-
Publication number: 20170252432Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: March 1, 2017Publication date: September 7, 2017Inventors: Martin Patrick Allen, Eric P. Gillis, David R. Langley, Michael Matthew Miller, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Katharine A. Grant-Young, Nicholas A. Meanwell, Paul Michael
-
Publication number: 20170107202Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: October 11, 2016Publication date: April 20, 2017Inventors: KAP-SUN YEUNG, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
-
Patent number: 9556162Abstract: The present invention provides (R)-5-(3-((2-(1,2,4-oxadiazol-3-yl)propan-2-yl)carbamoyl)phenyl)-6-(sec-butyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (formula I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compound. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: GrantFiled: December 8, 2014Date of Patent: January 31, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Kap-Sun Yeung, Katharine A. Grant-Young
-
Publication number: 20160318912Abstract: The present invention provides (R)-5-(3-((2-(1,2,4-oxadiazol-3-yl)propan-2-yl)carbamoyl)phenyl)-6-(sec-butyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (formula I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compound. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: ApplicationFiled: December 8, 2014Publication date: November 3, 2016Inventors: Kap-Sun Yeung, Katharine A. Grant-Young
-
Patent number: 8722688Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: GrantFiled: March 13, 2013Date of Patent: May 13, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Kap-Sun Yeung, Kyle E. Parcella, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, John F. Kadow, Andrew Nickel
-
Patent number: 8536338Abstract: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: GrantFiled: May 14, 2012Date of Patent: September 17, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Richard Pracitto, John F. Kadow, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, Andrew Nickel, Kyle E. Parcella, Kap-Sun Yeung, Louis S. Chupak
-
Patent number: 8354410Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: GrantFiled: March 9, 2011Date of Patent: January 15, 2013Assignee: Bristol-Meyers Squibb CompanyInventors: Kap-Sun Yeung, Katharine A. Grant-Young, John F. Kadow
-
Publication number: 20120316126Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: ApplicationFiled: August 17, 2012Publication date: December 13, 2012Inventors: Kap-Sun Yeung, Kyle E. Parcella, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, John F. Kadow, Andrew Nickel
-
Patent number: 8309558Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: GrantFiled: February 13, 2012Date of Patent: November 13, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Kap-Sun Yeung, Kyle E. Parcella, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, John F. Kadow, Andrew Nickel
